{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?sponsor=International+AIDS+Vaccine+Initiative",
    "query": {
      "sponsor": "International AIDS Vaccine Initiative"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 23,
    "total_pages": 3,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?sponsor=International+AIDS+Vaccine+Initiative&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-10-08T12:43:09.012Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00851383",
      "title": "A Trial to Evaluate Ad35-GRIN/ENV HIV Vaccine in Healthy Adult Volunteers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "HIV",
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "Ad35-GRIN/ENV",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Ad35-GRIN",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "International AIDS Vaccine Initiative",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 56,
      "start_date": "2009-03",
      "completion_date": "2011-08",
      "has_results": false,
      "last_update_posted_date": "2012-04-25",
      "last_synced_at": "2026-10-08T12:43:09.012Z",
      "location_count": 1,
      "location_summary": "Rochester, New York",
      "locations": [
        {
          "city": "Rochester",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00851383"
    },
    {
      "nct_id": "NCT05724472",
      "title": "Evaluation of Safety and Immunogenicity of rVSVΔG-SEBOV-GP Vaccine in Adults With Good General Health",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Ebola Sudan Virus Disease"
      ],
      "interventions": [
        {
          "name": "rVSV∆G-SEBOV-GP Vaccine or Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "International AIDS Vaccine Initiative",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 36,
      "start_date": "2023-06-19",
      "completion_date": "2024-01-09",
      "has_results": false,
      "last_update_posted_date": "2024-11-06",
      "last_synced_at": "2026-10-08T12:43:09.012Z",
      "location_count": 2,
      "location_summary": "Austin, Texas • San Antonio, Texas",
      "locations": [
        {
          "city": "Austin",
          "state": "Texas"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05724472"
    },
    {
      "nct_id": "NCT03205917",
      "title": "A Clinical Trial of PGDM1400 and PGT121 and VRC07-523LS Monoclonal Antibodies in HIV-infected and HIV-uninfected Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "PGDM1400/Placebo (3mg/kg IV)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "PGDM1400/Placebo (10mg/kg IV)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "PGDM1400/Placebo (30mg/kg IV)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "PGDM1400 + PGT121/Placebo (3mg/kg + 3mg/kg IV)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "PGDM1400 + PGT121/Placebo (10mg/kg + 10mg/kg IV)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "PGDM1400 + PGT121/Placebo (30mg/kg + 30mg/kg IV)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "PGDM1400 + PGT121 + VRC07-523LS (20mg/kg + 20mg/kg + 20 mg/kg IV)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "PGDM1400 + PGT121 (MTD IV)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "International AIDS Vaccine Initiative",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 29,
      "start_date": "2017-10-23",
      "completion_date": "2020-04-20",
      "has_results": false,
      "last_update_posted_date": "2020-09-14",
      "last_synced_at": "2026-10-08T12:43:09.012Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03205917"
    },
    {
      "nct_id": "NCT00252148",
      "title": "Safety and Immunogenicity of a Modified Vaccinia Ankara (MVA) HIV Vaccine in HIV Uninfected Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "HIV Infection"
      ],
      "interventions": [
        {
          "name": "ADMVA",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "International AIDS Vaccine Initiative",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "40 Years",
        "sex": "ALL",
        "summary": "18 Years to 40 Years"
      },
      "enrollment_count": 48,
      "start_date": "2005-01",
      "completion_date": "2007-08",
      "has_results": false,
      "last_update_posted_date": "2013-02-11",
      "last_synced_at": "2026-10-08T12:43:09.012Z",
      "location_count": 2,
      "location_summary": "New York, New York • Rochester, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Rochester",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00252148"
    },
    {
      "nct_id": "NCT05001373",
      "title": "A Phase 1 Study to Evaluate the Safety and Immunogenicity of eOD-GT8 60mer mRNA Vaccine (mRNA-1644) and Core-g28v2 60mer mRNA Vaccine (mRNA-1644v2-Core)",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Hiv"
      ],
      "interventions": [
        {
          "name": "Core-g28v2 60mer mRNA Vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "eOD-GT8 60mer mRNA Vaccine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "International AIDS Vaccine Initiative",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 56,
      "start_date": "2021-11-12",
      "completion_date": "2024-07-01",
      "has_results": false,
      "last_update_posted_date": "2024-05-01",
      "last_synced_at": "2026-10-08T12:43:09.012Z",
      "location_count": 4,
      "location_summary": "Washington D.C., District of Columbia • Atlanta, Georgia • San Antonio, Texas + 1 more",
      "locations": [
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05001373"
    },
    {
      "nct_id": "NCT07565090",
      "title": "A Clinical Study to Investigate the Safety and Immunogenicity of rVSV∆G-SUDV-GP, a Sudan Virus (SUDV) Vaccine for the Prevention of SUDV Disease in Adults in Good General Health",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Sudan Virus Disease"
      ],
      "interventions": [
        {
          "name": "rVSVΔG-SUDV-GP",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "International AIDS Vaccine Initiative",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 112,
      "start_date": "2026-05-08",
      "completion_date": "2027-04",
      "has_results": false,
      "last_update_posted_date": "2026-09-21",
      "last_synced_at": "2026-10-08T12:43:09.012Z",
      "location_count": 3,
      "location_summary": "Washington D.C., District of Columbia • Lenexa, Kansas • Boston, Massachusetts",
      "locations": [
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Lenexa",
          "state": "Kansas"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07565090"
    },
    {
      "nct_id": "NCT03699241",
      "title": "A Randomized, Double-blinded, Placebo-controlled, Dose-escalation Phase 1 Clinical Trial to Evaluate the Safety and Immunogenicity of Recombinant HIV Envelope Protein BG505 SOSIP.664 gp140 Vaccine, Adjuvanted, in Healthy, HIV-1 Uninfected Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "BG505 SOSIP.664 gp140, adjuvanted",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "International AIDS Vaccine Initiative",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 61,
      "start_date": "2018-12-03",
      "completion_date": "2023-07-11",
      "has_results": false,
      "last_update_posted_date": "2023-12-14",
      "last_synced_at": "2026-10-08T12:43:09.012Z",
      "location_count": 2,
      "location_summary": "Boston, Massachusetts • Seattle, Washington",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03699241"
    },
    {
      "nct_id": "NCT02960581",
      "title": "Safety, PK and Antiviral Activity of PGT121 Monoclonal Antibody in HIV-uninfected and HIV-infected Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "HIV Infection"
      ],
      "interventions": [
        {
          "name": "PGT121 3mg/kg IV",
          "type": "BIOLOGICAL"
        },
        {
          "name": "PGT121 10mg/kg IV",
          "type": "BIOLOGICAL"
        },
        {
          "name": "PGT121 30mg/kg IV",
          "type": "BIOLOGICAL"
        },
        {
          "name": "PGT121 3mg/kg SC",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo (0.9% Sodium Chloride Injection USP (Saline))",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "International AIDS Vaccine Initiative",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 48,
      "start_date": "2016-11",
      "completion_date": "2019-07-08",
      "has_results": false,
      "last_update_posted_date": "2019-09-17",
      "last_synced_at": "2026-10-08T12:43:09.012Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02960581"
    },
    {
      "nct_id": "NCT02366013",
      "title": "Trial of the Safety and Immunogenicity of an Oral, Replicating Ad26 Vectored HIV-1 Vaccine",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "HIV"
      ],
      "interventions": [
        {
          "name": "rcAd26.MOS1.HIV-Env 1x10^8 vp",
          "type": "BIOLOGICAL"
        },
        {
          "name": "rcAd26.MOS1.HIV-Env 1x10^9 vp",
          "type": "BIOLOGICAL"
        },
        {
          "name": "rcAd26.MOS1.HIV-Env 1x10^10 vp",
          "type": "BIOLOGICAL"
        },
        {
          "name": "rcAd26.MOS1.HIV-Env 1x10^11 vp",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "International AIDS Vaccine Initiative",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "40 Years",
        "sex": "ALL",
        "summary": "18 Years to 40 Years"
      },
      "enrollment_count": 22,
      "start_date": "2015-01",
      "completion_date": "2016-06",
      "has_results": false,
      "last_update_posted_date": "2016-11-21",
      "last_synced_at": "2026-10-08T12:43:09.012Z",
      "location_count": 1,
      "location_summary": "Rochester, New York",
      "locations": [
        {
          "city": "Rochester",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02366013"
    },
    {
      "nct_id": "NCT01195571",
      "title": "Safety Study of Four Chimera Cytomegalovirus (CMV) Vaccines in Healthy Adult Males 30-50 Years of Age",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Cytomegalovirus"
      ],
      "interventions": [
        {
          "name": "cmv vaccine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "CMV Research Foundation",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "30 Years",
        "maximum_age": "50 Years",
        "sex": "MALE",
        "summary": "30 Years to 50 Years · Male only"
      },
      "enrollment_count": 36,
      "start_date": "2010-09",
      "completion_date": "2014-10",
      "has_results": false,
      "last_update_posted_date": "2015-05-19",
      "last_synced_at": "2026-10-08T12:43:09.012Z",
      "location_count": 1,
      "location_summary": "Richmond, Virginia",
      "locations": [
        {
          "city": "Richmond",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01195571"
    }
  ]
}